Inarigivir soproxil, Inhibitor

Inarigivir soproxil

Cat. Num. AAA5754993

• Purity: 98.35%
• Synonyms: Inarigivir soproxil; SB9200; inhibitor

• Purity/Purification: 98.35%
• Form/Format: Solid. Powder

• Solubility: DMSO: 102mg/mL (144.96mM); (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: C25H34N7O13PS
• SMILES: CO[C@@H]1[C@H](OP(=O)(OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)SCOC(=O)OC(C)C)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O
• CAS Number: 942123-43-5
• Target & IC50: HCV 1a/1b: ic50 2.2/1.0uM (EC50); HCV
• In Vitro: Inarigivir soproxil is shown to inhibit HCV replication and the range of inhibition is comparable between genotypes 1a and 1b. Inarigivir soproxil is an oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil demonstrates pan-genotypic antiviral activity against HCV. Inarigivir soproxil is active against DAA-resistant HCV variants. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV)[1].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Structure

Related Product Information for Inarigivir soproxil, inhibitor

Inarigivir soproxil is an agonist of innate immunity. It also displays effective antiviral activity against resistant hepatitis C virus (HCV) variants (EC50s of 2.2 and 1.0uM for HCV 1a/1b in cells of genotype 1 HCV replicon systems).

Product Categories/Family for Inarigivir soproxil, inhibitor

Microbiology&virology; Proteases/Proteasome

References

Jones M, ET AL. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628.
Jones M, ET AL. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628.